Male breast cancer: tamoxifen improves DFS in German cohort

  • Eggemann H & al.
  • Br J Cancer
  • 5 May 2020

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A prospective cohort study finds that tamoxifen (vs no tamoxifen) treatment reduces the recurrence rate by 62% in men with breast cancer.

Why this matters

  • These results are from the first prospective cohort study of the benefits of tamoxifen in men with breast cancer.

Study design

  • Prospective multicenter cohort study of 448 men in the German national prospective cancer registry.
  • DFS is defined as the interval between the date of diagnosis and locoregional recurrence, distant recurrence, or death (whichever occurs first).
  • Funding: None.

Key results

  • Median follow-up was 39 (range, 2-89) months.
  • Most tumors were >20 mm.
  • 43.5% of men had positive axillary lymph nodes.
  • 98.4% of men had hormone receptor positivity.
  • DFS in men not receiving tamoxifen was lower compared with those receiving tamoxifen (P=.002).
  • Tamoxifen recipients had a lower rate of recurrence or death as a single category (13.9% vs 22.6%) compared with those not receiving tamoxifen.
    • Tamoxifen reduced the recurrence rate by 62% (HR, 0.38; P=.008) after adjustment for numerous factors.
  • The most frequent metastatic sites were the bone followed by locoregional sites, liver, lungs and/or pleura, distant lymph nodes, brain, and rectum.

Limitations

  • Observational design.